Home 2018-12-05T04:07:09+00:00

Giving Hope.

From the minute you walk through our door,
our focus is on you.

OFFICE HOURS

Mon – Thurs 8:00am – 4:30pm
Friday 8:00am – 12:00pm

704.947.6599

Welcome to
Carolina BioOncology Institute

At Carolina BioOncology Institute we care for the person, and the disease.

OUR HEALTH SERVICES

OUR FOUNDER

John Powderly, MD  CPI

President  |  CEO

Dr. John Powderly attended Georgetown Medical School from 1991-95 and was awarded the Lawrence Dean Scholarship. His 4th year of Med School was spent at National Cancer Institute (NCI) as an internship on the Immunotherapy Service.   From 1995-1999 he attended the University of Texas, at Houston Health Science Center for a combined Medicine/Pediatrics Residency. In 1999-2000 he was appointed faculty at MD Anderson Cancer Center and performed additional immunotherapy research.  His oncology fellowship at University of North Carolina, Chapel Hill from 2000-02 focused on dendritic cell immunotherapy.

OUR TEAM

Carolina BioOncology Institute has gathered a word class team of medical professionals dedicated to furthering the health and welfare of each patient that comes through our doors. For a detailed view of each team member please click the button below.

MEET OUR TEAM

TOUR OUR FACILITIES

You’re invited to come by and get a complete tour of our facilities.

CLINICAL TRIALS

Clinical trial participants have the opportunity to receive new research treatments before they are widely available. With Phase 1 clinical trial units at our headquarters in Huntersville, NC, we’re able to enroll patients in the newest, most promising trials, without the need for long-distance travel.

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects with Locally Advanced or Metastatic Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT03071757?term=m16-074&rank=1

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects with Advanced Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT02988960?term=m15-862&rank=1

An Open Label, Phase 1 Study of SC-006 as a Single Agent and in Combination with ABBV-181 in Subjects with Advanced Colorectal Cancer

https://clinicaltrials.gov/ct2/show/NCT03035279?term=m16-312&rank=1

A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT03595059?term=m16-573&rank=1

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT03059823?term=incmga0012&rank=5

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

https://clinicaltrials.gov/ct2/show/NCT02655822?term=cpi-444&rank=2

A Phase 1/1b Multicenter STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT, IN COMBINATION WITH CPI-444, AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

https://clinicaltrials.gov/ct2/show/NCT03454451?term=cpi-006-001&rank=1

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies

https://clinicaltrials.gov/ct2/show/NCT03474640?term=tab001-01&rank=1

A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma.

https://clinicaltrials.gov/ct2/show/NCT03531632?term=mgd007-02&rank=1

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

https://clinicaltrials.gov/ct2/show/NCT03538028?term=incagn2385&rank=1

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies.

https://clinicaltrials.gov/ct2/show/NCT03652077?term=incagn2390&rank=1

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer.

https://clinicaltrials.gov/ct2/show/NCT03674567?term=flx475-02&rank=1

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies.

https://clinicaltrials.gov/ct2/show/NCT03719326?term=AB928&rank=3

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Gastrointestinal Malignancies.

https://clinicaltrials.gov/ct2/show/NCT03720678?term=AB928&rank=2

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors.

https://clinicaltrials.gov/ct2/show/NCT03729596?term=mgc018&rank=1